Back to search

Article

SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice

2020-11-05

Abstract excerpt

There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast ( Pichia pastoris ), as a suitable vaccine candidate against COVID-19. After introducing two modifications into the wild-type RBD gene to reduce yeast-derived hyperglycosylat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
90280517-5418-53de-9788-6bea0397e830
DOI
10.1101/2020.11.04.367359
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceDOI 10.1101/2020.11.04.367359
Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity
Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infectionSemantic proximity
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity
Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity
Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1Semantic proximity
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessSemantic proximity
Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in miceSemantic proximity
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity
A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.Semantic proximity
Select a neighboring publication to make it the new centre.